Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Pregnant women with opioid use disorder can be treated with methadone, buprenorphine, or naltrexone to reduce opioid use and improve retention to treatment. In this review, we compare the pregnancy outcomes of methadone, buprenorphine, and naltrexone in clinical trials and discuss the potential behavioral and developmental effects of these agents seen in offspring in animal studies. Important clinical considerations in the management of opioid use disorder in pregnant women and their infants are also discussed. Outside of pregnancy, buprenorphine is used in combination with naloxone to reduce opioid abuse and diversion. During pregnancy, however, the use of buprenorphine as a single agent is preferred to prevent prenatal naloxone exposure. Both methadone and buprenorphine are widely used to treat opioid use disorder; however, compared with methadone, buprenorphine is associated with shorter treatment duration, less medication needed to treat neonatal abstinence syndrome ( NAS ) symptoms, and shorter hospitalizations for neonates. Despite being the standard of care, medication‐assisted treatment with methadone or buprenorphine is still underused, making it apparent that more options are necessary. Naltrexone is not a first‐line treatment primarily because both detoxification and an opioid‐free period are required. More research is needed to determine naltrexone safety and benefits in pregnant women. Animal studies suggest that changes in pain sensitivity, developmental processes, and behavioral responses may occur in children born to mothers receiving methadone, buprenorphine, or naltrexone and is an area that warrants future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
Neonatal Abstinence Syndrome and Associated Health Care Expenditures: United States, 2000-2009
Patrick, S. W., Schumacher, R. E., Benneyworth, B. D., Krans, E. E., McAllister, J. M., & Davis, M. M. (2012) · JAMA · doi:10.1001/jama.2012.3951 · Cited by 907
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Veilleux, J. C., Colvin, P. J., Anderson, J., York, C., & Heinz, A. J. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.10.006 · Cited by 336
Cited by
Crotty, K., Freedman, K. I., & Kampman, K. M. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000635 · Cited by 95
Nakamura, A., Yasufuku, K., Shimada, S., Aritomi, H., Furue, Y., Chiba, H., Muramoto, M., Takase, K., Koike, K., Matsumoto, T., et al. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135177 · Cited by 9
“administration route to attain a larger magnitude of euphoria and many abuse-deterrent approaches including formulating agonist/ antagonist combinations [6], adding aversive agents [7], modifying the delivery system [8], and developing prodrugs [9] have been challenged.”
Gopalan, P., Moses-Kolko, E., Valpey, R., Shenai, N., & Smith, E. (2019) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2018.12.005 · Cited by 5
Metadata
- Authors
- Tran, T. H., Griffin, B. L., Stone, R. H., Vest, K. M., & Todd, T. J.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2017-07
- Volume
- 37
- Issue
- 7
- Pages
- 824-839
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2618994494
- Cited by
- 73
- References
- 5
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women. https://app.cochat.ai/papers/10.1002/phar.1958
- The paper
- Tran, T. H., Griffin, B. L., Stone, R. H., Vest, K. M., & Todd, T. J. (2017). Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.1958
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.